PURPOSE: We investigated how treatment-induced neuropathic symptoms are associated with patients' quality of life (QOL) and clinician-reported difficulty in caring for patients. METHODS: Data were obtained from 3,106 outpatients with colorectal, breast, lung, or prostate cancer on numbness/tingling (N/T), neuropathic pain, and QOL. Clinicians reported the degree of difficulty in caring for patients' physical and psychological symptoms. RESULTS: For all patients, moderate to severe N/T was associated with poor QOL (OR = 1.82, 95% CI = 1.47-2.26, P < 0.001) but neuropathic pain was not (OR = 1.31, 95% CI = 0.94-1.83, P = 0.114). Moderate to severe N/T and neuropathic pain were associated with increased care difficulty (OR = 1.49, 95% CI = 1.27-1.74, P < 0.001 for N/T, and OR = 1.46, 95% CI = 1.15-1.84, P = 0.002 for neuropathic pain). The association of neuropathic pain with care difficulty was most significant in patients with colorectal cancer (CRC) (OR = 2.32, 95% CI = 1.41-3.83, P = 0.001). Baseline neuropathic pain was associated with declining QOL in CRC patients (OR = 2.08, 95% CI = 1.21-3.58, P = 0.008). CONCLUSIONS: Clinicians may experience increased care difficulty for patients of all cancer types with moderate to severe N/T or neuropathic pain; care difficulty due to neuropathic pain may be higher for CRC patients. Nearly half the patients of all cancer types with moderate to severe N/T may expect poor short-term QOL; CRC-but not other-patients with baseline neuropathic pain are likely to experience declining QOL. IMPLICATIONS FOR CANCER SURVIVORS: About half of patients with moderate to severe N/T (any cancer type) may expect poor QOL in the short term; CRC patients with baseline neuropathic pain in particular may experience declining QOL.
PURPOSE: We investigated how treatment-induced neuropathic symptoms are associated with patients' quality of life (QOL) and clinician-reported difficulty in caring for patients. METHODS: Data were obtained from 3,106 outpatients with colorectal, breast, lung, or prostate cancer on numbness/tingling (N/T), neuropathic pain, and QOL. Clinicians reported the degree of difficulty in caring for patients' physical and psychological symptoms. RESULTS: For all patients, moderate to severe N/T was associated with poor QOL (OR = 1.82, 95% CI = 1.47-2.26, P < 0.001) but neuropathic pain was not (OR = 1.31, 95% CI = 0.94-1.83, P = 0.114). Moderate to severe N/T and neuropathic pain were associated with increased care difficulty (OR = 1.49, 95% CI = 1.27-1.74, P < 0.001 for N/T, and OR = 1.46, 95% CI = 1.15-1.84, P = 0.002 for neuropathic pain). The association of neuropathic pain with care difficulty was most significant in patients with colorectal cancer (CRC) (OR = 2.32, 95% CI = 1.41-3.83, P = 0.001). Baseline neuropathic pain was associated with declining QOL in CRCpatients (OR = 2.08, 95% CI = 1.21-3.58, P = 0.008). CONCLUSIONS: Clinicians may experience increased care difficulty for patients of all cancer types with moderate to severe N/T or neuropathic pain; care difficulty due to neuropathic pain may be higher for CRCpatients. Nearly half the patients of all cancer types with moderate to severe N/T may expect poor short-term QOL; CRC-but not other-patients with baseline neuropathic pain are likely to experience declining QOL. IMPLICATIONS FOR CANCER SURVIVORS: About half of patients with moderate to severe N/T (any cancer type) may expect poor QOL in the short term; CRCpatients with baseline neuropathic pain in particular may experience declining QOL.
Authors: Janet M Schloss; Maree Colosimo; Caroline Airey; Paul P Masci; Anthony W Linnane; Luis Vitetta Journal: Clin Nutr Date: 2013-04-13 Impact factor: 7.324
Authors: Ellen M Lavoie Smith; Herbert Pang; Constance Cirrincione; Stewart Fleishman; Electra D Paskett; Tim Ahles; Linda R Bressler; Camilo E Fadul; Chetaye Knox; Nguyet Le-Lindqwister; Paul B Gilman; Charles L Shapiro Journal: JAMA Date: 2013-04-03 Impact factor: 56.272
Authors: Cindy Tofthagen; Kristine A Donovan; Mary Ann Morgan; David Shibata; Yating Yeh Journal: Support Care Cancer Date: 2013-08-01 Impact factor: 3.603
Authors: Brandi N Reeves; Shaker R Dakhil; Jeff A Sloan; Sherry L Wolf; Kelli N Burger; Arif Kamal; Nguyet A Le-Lindqwister; Gamini S Soori; Anthony J Jaslowski; Joseph Kelaghan; Paul J Novotny; Daniel H Lachance; Charles L Loprinzi Journal: Cancer Date: 2012-03-13 Impact factor: 6.860
Authors: Charles L Loprinzi; Brandi N Reeves; Shaker R Dakhil; Jeff A Sloan; Sherry L Wolf; Kelli N Burger; Arif Kamal; Nguyet A Le-Lindqwister; Gamini S Soori; Anthony J Jaslowski; Paul J Novotny; Daniel H Lachance Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Paul Lennart Vollmers; Christoph Mundhenke; Nicolai Maass; Dirk Bauerschlag; Stefan Kratzenstein; Christoph Röcken; Thorsten Schmidt Journal: J Cancer Res Clin Oncol Date: 2018-06-25 Impact factor: 4.553
Authors: So Yeon Oh; Sang Won Shin; Su-Jin Koh; Sang Byung Bae; Hyun Chang; Jung Han Kim; Hyo Jung Kim; Young Seon Hong; Keon Uk Park; Jeanno Park; Kyung Hee Lee; Na Ri Lee; Jung Lim Lee; Joung Soon Jang; Dae Sik Hong; Seung-Sei Lee; Sun Kyung Baek; Dae Ro Choi; Jooseop Chung; Sang Cheul Oh; Hye Sook Han; Hwan Jung Yun; Sun Jin Sym; So Young Yoon; In Sil Choi; Byoung Yong Shim; Seok Yun Kang; Sung Rok Kim; Hyun Joo Kim Journal: Support Care Cancer Date: 2017-07-08 Impact factor: 3.603
Authors: Suvarna Gadgil; Mehmet Ergün; Sandra A van den Heuvel; Selina E van der Wal; Gert Jan Scheffer; Carlijn R Hooijmans Journal: PLoS One Date: 2019-08-28 Impact factor: 3.240